In accordance with the Federal Advisory Committee Act, HHS hereby gives notice that the National Advisory Committee on Rural Health and Human Services (NACRHHS) has been re-established. The effective date of the charter re-establishment is July 17, 2026.

Original title: “Charter Re-Establishment for the National Advisory Committee on Rural Health and Human Services”

The Office on Trafficking on Persons (OTIP), Administration for Children and Families (ACF), U.S. Department of Health and Human Services, is requesting to reinstate Office of Management and Budget (OMB) approval of an information collection, with proposed changes: National Human Trafficking Training and Technical Assistance Center (NHTTAC) Evaluation Package (OMB #: 0970-0519). The OMB number was discontinued due to delays in publishing the first Federal Register Notice. Data collection has bee

Original title: “Submission for Office of Management and Budget Review; National Human Trafficking Training and Technical Assistance Center Evaluation Package”

In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Board on Radiation and Worker Health (ABRWH). This is a hybrid meeting, accessible both in person and virtually. It is open to the public, limited only by the space available and the number of audio conference lines and internet conference access, with a public comment period. The public is welcome to submit written comments in advance of the

Original title: “Meeting of the Advisory Board on Radiation and Worker Health, National Institute for Occupational Safety and Health”

The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF), is requesting the Office of Management and Budget (OMB) to extend approval of the Income Withholding for Support (IWO), with changes, for an additional three years. The current OMB approval expires August 31, 2026.

Original title: “Submission for Office of Management and Budget Review; Income Withholding for Support”

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

Original title: “HHS plan to speed drug research won’t remove ‘self-inflicted’ delays”

An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy “contravenes decades of agency practice.”

Original title: “FDA freezes CRL trove as ‘radical transparency’ push hits speedbump”

Ordered to be Reported (Amended) by the Yeas and Nays: 20 - 16.

Original title: “HR 9605: Less Bureaucracy, Better Foreign Medical Accreditation Act”

The Food and Drug Administration (FDA, Agency, or we) has determined that TOVALT ODT (zolpidem tartrate) orally disintegrating tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for zolpidem tartrate, orally disintegrating tablets, 5 mg and 10 mg, if all other legal and regulatory requirements are met.

Original title: “Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness”

This notice acknowledges the Secretary of the Department of Health and Human Services' (the Secretary's) receipt and review of Battelle Memorial Institute's 2025 Annual Activities Report to Congress. The Battelle Memorial Institute is the consensus-based entity (CBE) under a contract with the Secretary, as mandated by section 1890(b)(5) of the Social Security Act (the Act). The Secretary has reviewed CBE's 2025 Annual Report and is publishing the report in the Federal Register together with the

Original title: “Secretarial Comments on the Consensus-Based Entity's (CBE) (Battelle Memorial Institute) 2025 Activities: Report to Congress and the Secretary of the Department of Health and Human Services”

Why the UK needs a unified strategy for chronic disease and adult vaccination

Original title: “The overlooked burden of ageing”

The Food and Drug Administration (FDA, the Agency, or we) is announcing a hybrid public meeting titled "Medical Device User Fee Amendments." The purpose of the public meeting is to discuss proposed recommendations for the reauthorization of the Medical Device User Fee Amendments (MDUFA) for fiscal years (FYs) 2028 through 2032. MDUFA authorizes FDA to collect fees and use them for the process for the review of device applications. The current legislative authority for MDUFA expires September 30,

Original title: “Medical Device User Fee Amendments; Public Meeting; Request for Comments”

In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide an opportunity for public comment on proposed data collection projects, the National Institutes of Health, National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Original title: “Proposed Collection; 60-Day Comment Request: Generic Clearance for the Collection of Customer Participation and Performance Management With NIH Programs, Products, and Services (Office of the Director)”

This notice announces the virtual meeting of the Advisory Panel on Hospital Outpatient Payment (the Panel) on Monday, August 24, 2026. The purpose of the Panel is to advise the Secretary of the Department of Health and Human Services on the clinical integrity of the Ambulatory Payment Classification groups and their associated weights, which are major elements of the Medicare Hospital Outpatient Prospective Payment System and the Ambulatory Surgical Center payment system, and supervision of hosp

Original title: “Medicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 24, 2026”

The Department of Health and Human Services (HHS), in consultation with the National Institutes of Health (NIH), is proposing to rescind the existing regulation concerning grants under the National Cancer Institute (NCI) Clinical Cancer Education Program because the regulation is obsolete and no longer necessary.

Original title: “Recission of the National Cancer Institute Clinical Cancer Education Program Regulation”

The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during January, February, and March 2026. The animal drug regulations are also being amended to improve their accuracy and readability.

Original title: “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor”

The Patient Safety and Quality Improvement Final Rule (Patient Safety Rule) authorizes AHRQ, on behalf of the Secretary of HHS, to list as a patient safety organization (PSO) an entity that attests that it meets the statutory and regulatory requirements for listing. A PSO can be "delisted" by the Secretary if it is found to no longer meet the requirements of the Patient Safety and Quality Improvement Act of 2005 (Patient Safety Act) and Patient Safety Rule, such as when a PSO chooses to voluntar

Original title: “Patient Safety Organizations: Voluntary Relinquishment for the Cassatt Patient Safety Organization”